Overview

Description

  • Nature
    Synthetic
  • Amino Acid Sequence
    • Species
      Human
    • Sequence
      C-REIEEEPLSEDLE
    • Amino acids
      703 to 715

Associated products

Specifications

Our Abpromise guarantee covers the use of ab22800 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Applications

    Blocking - Blocking peptide for Anti-FOXP2 antibody - C-terminal (ab1307)

  • Form
    Liquid
  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

General Info

  • Alternative names
    • CAG repeat protein 44
    • CAGH44
    • DKFZp686H1726
    • Forkhead box P2
    • Forkhead box protein P2
    • forkhead/winged-helix transcription factor
    • FOX P2
    • FOXP2
    • FOXP2_HUMAN
    • HGNC11222
    • HGNC11956
    • SPCH 1
    • SPCH1
    • TNRC 10
    • TNRC10
    • trinucleotide repeat containing 10
    • Trinucleotide repeat containing gene 10 protein
    • Trinucleotide repeat-containing gene 10 protein
    see all
  • Function
    Transcriptional repressor that may play a role in the specification and differentiation of lung epithelium. May also play a role in developing neural, gastrointestinal and cardiovascular tissues. Can act with CTBP1 to synergistically repress transcription but CTPBP1 is not essential. Involved in neural mechanisms mediating the development of speech and language.
  • Tissue specificity
    Isoform 1 and isoform 6 are expressed in adult and fetal brain, caudate nucleus and lung.
  • Involvement in disease
    Defects in FOXP2 are the cause of speech-language disorder 1 (SPCH1) [MIM:602081]; also known as autosomal dominant speech and language disorder with orofacial dyspraxia. Affected individuals have a severe impairment in the selection and sequencing of fine orofacial movements, which are necessary for articulation. They also show deficits in several facets of language processing (such as the ability to break up words into their constituent phonemes) and grammatical skills.
    Note=A chromosomal aberration involving FOXP2 is a cause of severe speech and language impairment. Translocation t(5;7)(q22;q31.2).
  • Sequence similarities
    Contains 1 C2H2-type zinc finger.
    Contains 1 fork-head DNA-binding domain.
  • Developmental stage
    Expressed in the brain at 15 and 22 weeks of gestation, with a pattern of strong cortical, basal ganglia, thalamic and cerebellar expression. Highly expressed in the head and tail of nucleus caudatus and putamen. Restricted expression within the globus pallidus, with high levels in the pars interna, which provides the principal source of output from the basal ganglia to the nucleus centrum medianum thalami (CM) and the major motor relay nuclei of the thalamus. In the thalamus, present in the CM and nucleus medialis dorsalis thalami. Lower levels are observed in the nuclei anterior thalami, dorsal and ventral, and the nucleus parafascicularis thalami. Expressed in the ventrobasal complex comprising the nucleus ventralis posterior lateralis/medialis. The ventral tier of the thalamus exhibits strong expression, including nuclei ventralis anterior, lateralis and posterior lateralis pars oralis. Also expressed in the nucleus subthalamicus bilaterally and in the nucleus ruber.
  • Domain
    The leucine-zipper is required for dimerization and transcriptional repression.
  • Cellular localization
    Nucleus.
  • Information by UniProt

References

ab22800 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

Question
Answer

Thank you for your enquiry. As we discussed over the phone, this peptide can be used to block specific binding of Ab1307, Goat polyclonal to FOXP2 antibody. Please find the blocking peptide protocol below. I hope this information helps, please do not hesitate to contact us if you need any more advice or information. Best of luck with your experiments! BLOCKING WITH IMMUNIZING PEPTIDE It is not uncommon to see more than 1 band in Western blotting when probing with a given antibody or to see more diffuse staining in immunolocalization studies. The question arises which band or staining is specific. The antibody specificity is generally studied by competing with excess antigen (peptide or protein) or immuno-neutralization with the antigens. In principle, a small volume of antibody (e.g., 1-5 µl) is first reacted with excess peptide (5-50 fold over the antibody; e.g., 1 µg antibody reacted with 5-50 µg peptide; exact amounts determined by titration) to neutralize it. The neutralized antibody can no longer bind to another antigen. So the band(s)/staining that is competed by the antigen/peptide is specific. If more than one band disappears by peptide/antigen competition then those bands have the antigenic determinants and could be considered either fragments of the large antigen or multimer. 1. Determine the amount of antibody that is needed for 1 strip (e.g., 2 ml). For example, an antibody has given desired bands at 1:1000 dilution. So you will need 1 µl/ml antibody (2-µl antibody for 2-ml antibody solution). If an antibody was used at 1:5000 dilution then you would only need 0.2 µl/ml (use 2 µl of 1:10 dilution for better accuracy). 2. Take 2-µl antibody (or as needed) in 100 µl saline/PBS. Make 2 tubes. Add antigen/peptide solution (10-50 µg peptide or antigen added in 10-100 µl). Add same volume of saline/PBS (no peptide/antigen) to the other tube labeled as “no peptide”. Mix gently. 3. Incubate both tubes at 37°C for 1-2 hrs or 2-24 hrs at 4oC. 4. Centrifuge the tubes for 15 min at 4°C in a microfuge (10-15000 rpm) to pellet any immune complexes. Carefully remove the supernatant. If no visible pellet is seen then just leave approx. 5-10 µl at the bottom to avoid disturbing invisible immune complexes. If you do not centrifuge the solution, it may give high background. 5. After centrifugation, make up the volume of supernatant to 2 ml (or what is necessary depending upon the initial antibody taken) with buffer (PBSTween with or without BSA or milk or any buffer that was used initially). Use both antibodies (with and without antigen/peptide) for Western blotting or immunolocalization. 6. Observe the bands/staining that disappears.

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up